| Revenue | NOK 667K | -10% |
| EBITDA | NOK 32K | -46% |
| Net profit | NOK -173K | -22% |
| Total assets | NOK 3,1M | -6% |
| Equity | NOK 1,1M | -14% |
| Employees | 0 | — |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 983 | 1 104 | 1 193 | 738 | 667 |
| Staff expenses | −36 | −0 | −0 | −0 | −0 |
| EBITDA | 468 | 298 | 106 | 59 | 32 |
| Depreciation & amort. | −195 | −194 | −156 | −120 | −120 |
| EBIT | 273 | 104 | −50 | −61 | −88 |
| Net financials | −95 | −81 | −70 | −81 | −85 |
| Profit before tax | 177 | 22 | −121 | −141 | −173 |
| Tax | 39 | 5 | −17 | −0 | −0 |
| Net profit | 138 | 17 | −104 | −141 | −173 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3 679 | 3 492 | 3 386 | 3 335 | 3 126 |
| Equity | 1 455 | 1 473 | 1 369 | 1 227 | 1 054 |
| Long-term debt | 1 990 | 1 698 | 1 517 | 1 494 | 1 583 |
| Short-term debt | 234 | 321 | 501 | 614 | 488 |
| Total debt | 2 223 | 2 019 | 2 018 | 2 108 | 2 072 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KD Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (1) | ||
TM Chief Executive Officer | Chief Executive Officer | 2011 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2022 | |
| Former (2) | ||
| Chairman | 2011 – 2022 | |
| Board of Directors | 2011 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 | |
M E Kval Holding As | Company | 50% | 50% | 2022 |
| Company | 50% | 50% | 2022 |
| Person | Role here | Other companies |
|---|---|---|
| Kristian Druglimo | Chief Executive Officer | 0 companies |
| Tom Malme Gundersen | Chief Executive Officer | 0 companies |
| Erik Alver | Chairman | 0 companies |
| Morten Roland Kval | Board of Directors | 0 companies |
| Marit Storvik | Chairman | 0 companies |